Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma

The Lancet Respiratory Medicine

Volumn 4, Issue 7, 2016, Pages 585-592

  Trivedi, Abhaya ^a   Pavord, Ian D ^b   Castro, Mario ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENRALIZUMAB; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DUPILUMAB; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; LEBRIKIZUMAB; MEPOLIZUMAB; OMALIZUMAB; RESLIZUMAB; ANTIASTHMATIC AGENT;

ALLERGIC ASTHMA; ASTHMA; BRONCHIAL THERMOPLASTY DEVICE; BRONCHOCONSTRICTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEVICE APPROVAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EOSINOPHIL COUNT; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BIOLOGICAL THERAPY; BRONCHIAL THERMOPLASTY; LOEFFLER PNEUMONIA; PATHOLOGY; PHENOTYPE; PROCEDURES; SEVERITY OF ILLNESS INDEX;

ANTI-ASTHMATIC AGENTS; ASTHMA; BIOLOGICAL THERAPY; BRONCHIAL THERMOPLASTY; DISEASE PROGRESSION; HUMANS; OMALIZUMAB; PHENOTYPE; PULMONARY EOSINOPHILIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84971667587     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30018-2     Document Type: Review

References (55)

1. 1 Moore, WC, Bleecker, ER, Curran-Everett, D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 119 (2007), 405–413.
2. 2 Chung, KF, Wenzel, SE, Brozek, JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43 (2014), 343–373.
3. 3 Amelink, M, de Groot, JC, de Nijs, SB, et al. Severe adult-onset asthma: a distinct phenotype. J Allergy Clin Immunol 132 (2013), 336–341.
4. 4 Wenzel, S, Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 18 (2012), 716–725.
5. 5 Cohen, L, Xueping, E, Tarsi, J, et al. Epithelial cell proliferation contributes to airway remodeling in severe asthma. Am J Respir Crit Care Med 176 (2007), 138–145.
6. 6 Carroll, N, Elliot, J, Morton, A, James, A, The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 147 (1993), 405–410.
7. 7 Moore, W, Meyers, D, Wenzel, S, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Resp Crit Care Med 181 (2010), 315–323.
8. 8 Haldar, P, Pavord, I, Shaw, D, et al. Cluster analysis and clinical asthma phenotypes. Am J Resp Crit Care Med 178 (2008), 218–224.
9. 9 Wills-Karp, M, Luyimbazi, J, Xu, X, et al. Interleukin-13: central mediator of allergic asthma. Science 282 (1998), 2258–2261.
10. 10 Gauthier, M, Ray, A, Wenzel, S, Evolving concepts of asthma. Am J Respir Crit Care Med 192 (2015), 660–668.
11. 11 Woodruff, PG, Modrek, B, Choy, DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 180 (2009), 388–395.
12. 12 Milgrom, H, Fick, R Jr, Su, J, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 341 (1999), 1966–1973.
13. 13 Katial, R, Strand, M, Prasertsuntarasai, T, Leung, R, Zheng, W, Alam, R, The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol 126 (2010), 738–744.
14. 14 Gevaert, P, Van Bruaene, N, Cattaert, T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 128 (2011), 989–995.
15. 15 Wenzel, S, Ford, L, Pearlman, D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368 (2013), 2455–2466.
16. 16 Corren, J, Lemanske, RF, Hanania, NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 365 (2011), 1088–1098.
17. 17 Castro, M, Wenzel, SE, Bleecker, ER, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomized dose-ranging study. Lancet Respir Med 2 (2014), 879–890.
18. 18 Ortega, H, Liu, M, Pavord, I, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371 (2014), 1198–1207.
19. 19 Brusselle, GG, Vanderstichele, C, Jordens, P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 68 (2013), 322–329.
20. 20 Wong, EH, Porter, JD, Edwards, MR, Johnston, SL, The role of macrolides in asthma: current evidence and future directions. Lancet Respir Med 2 (2014), 657–670.
21. 21 Nair, P, Pizzichini, M, Kjarsgaard, M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360 (2009), 985–993.
22. 22 Larose, M, Chakir, J, Archambault, A, et al. Correlation between CCL26 production by human bronchial epithelial cells and airway eosinophils: involvement in patients with severe eosinophilic asthma. J Allergy Clin Immunol 136 (2015), 904–913.
23. 23 Aysola, RS, Hoffman, EA, Gierada, D, et al. Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology. Chest 134 (2008), 1183–1191.
24. 24 Haldar, P, Brightling, C, Hargadon, B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360 (2009), 973–984.
25. 25 Cox, G, Thomson, N, Rubin, A, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med 356 (2007), 1327–1337.
26. 26 Solway, J, Irvin, C, Airway smooth muscle as a target for asthma therapy. N Engl J Med 356 (2007), 1367–1369.
27. 27 Castro, M, Rubin, A, Laviolette, M, et al. Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma. Ann Allergy Asthma Immunol 107 (2011), 65–70.
28. 28 Castro, M, Rubin, AS, Laviolette, M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 181 (2010), 116–124.
29. 29 Pavord, ID, Cox, G, Thomson, NC, et al. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med 176 (2007), 1185–1191.
30. 30 Pavord, ID, Thomson, NC, Niven, RM, et al. Safety of bronchial thermoplasty in patients with severe refractory asthma. Ann Allergy Asthma Immunol 111 (2013), 402–407.
31. 31 Wechsler, M, Laviolette, M, Rubin, A, et al. Bronchial thermoplasty-long term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol 132 (2013), 1295–1302.
32. 32 Denner, D, Doeing, D, Hogarth, D, Dugan, K, Naureckas, E, White, S, Airway inflammation after bronchial thermoplasty for severe asthma. Ann Am Thorac Soc 12 (2015), 1302–1309.
33. 33 Chakir, J, Haj-Salem, I, Gras, D, et al. Effects of bronchial thermoplasty on airway smooth muscle and collagen deposition in asthma. Ann Am Thorac Soc 12 (2015), 1612–1618.
34. 34 Pretolani, M, Dombret, M, Thabut, G, et al. Reduction of airway smooth muscle mass by bronchial thermoplasty in patients with severe asthma. Am J Respir Crit Care Med 190 (2014), 1452–1454.
35. 35 Bergqvist, A, Pretolani, M, Taille, C, et al. Selective structural changes following bronchial thermoplasty. Am J Respir Crit Care Med, 191, 2015, A4171.
36. 36 Sarikonda, K, Sheshadri, A, Koch, T, et al. Predictors of bronchial thermoplasty response in patients with severe refractory asthma. Am J Respir Crit Care Med, 189, 2014, A2429.
37. 37 Licari, A, Marseglia, G, Castagnoli, R, Marseglia, A, Ciprandi, G, The discovery and development of omalizumab for the treatment of asthma. Expert Opin Drug Discov 10 (2015), 1033–1042.
38. 38 Normansell, R, Walker, S, Milan, S, Walters, E, Nair, P, Omalizumab for asthma in adults and children. Cochrane Database Syst Rev, 13, 2014 CD003559.
39. 39 Hanania, N, Alpan, O, Hamilos, DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 154 (2011), 573–582.
40. 40 Hanania, NA, Wenzel, S, Rosén, K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 187 (2013), 804–811.
41. 41 Green, R, Brightling, C, McKenna, S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360 (2002), 1715–1721.
42. 42 Pavord, I, Korn, S, Howarth, P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380 (2012), 651–659.
43. 43 Bel, E, Wenzel, S, Thompson, P, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371 (2014), 1189–1197.
44. 44 Castro, M, Mathur, S, Hargreave, F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 184 (2011), 1125–1132.
45. 45 Castro, M, Zangrilli, J, Wechsler, ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3 (2015), 355–366.
46. 46 Laviolette, M, Gossage, D, Gauvreau, G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 132 (2013), 1086–1096.
47. 47 Hanania, N, Noonan, M, Corren, J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 70 (2015), 748–756.
48. 48 Byers, DE, Defining the roles of IL-33, thymic stromal lymphopoietin, and IL-25 in human asthma. Am J Respir Crit Care Med 190 (2014), 715–716.
49. 49 Byers, DE, Alexander-Brett, J, Patel, AC, et al. Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Invest 123 (2013), 3967–3982.
50. 50 Gauvreau, GM, O'Byrne, PM, Boulet, LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 370 (2014), 2102–2110.
51. 51 Cheng, D, Xue, Z, Yi, L, et al. Epithelial interleukin-25 is a key mediator in Th2-high corticosteroid-responsive asthma. Am J Respir Crit Care Med 190 (2014), 639–648.
52. 52 Castro, M, Fain, SB, Hoffman, EA, et al. Lung imaging in asthmatic patients: the picture is clearer. J Allergy Clin Immunol 128 (2011), 467–478.
53. 53 Thomen, R, Sheshadri, A, Quirk, J, et al. Regional ventilation changes in severe asthma after bronchial thermoplasty by 3He MRI and CT. Radiology 274 (2015), 250–259.
54. 54 Zein, J, Menegay, M, Singer, M, et al. Cost effectiveness of bronchial thermoplasty in patients with severe uncontrolled asthma. J Asthma 53 (2016), 194–200.
55. 55 Zafari, Z, Sadatsafavi, M, Marra, CA, Chen, W, FitzGerald, JM, Cost-effectiveness of bronchial thermoplasty, omalizumab, and standard therapy for moderate-to-severe allergic asthma. PLoS One, 11, 2016, e0146003.